Effectiveness of Repetitive Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder

Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Patients With Treatment Non-Response Obsessive-Compulsive Disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210818052221N1

Enrollment

Registered

2021-10-18

Start date

2021-10-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: A 1 Hz repetitive transcranial magnetic field will be performed on the lateral dorsal side of the left frontal cortex (L-DLPFC) for 20 sessions 3 times per week. In

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All persons over 18 years of age and right-handed who have complete diagnostic criteria for obsessive-compulsive disorder based on the diagnostic and statistical manual of mental disorders According to the standard Yale-Brown scale, the diagnosis of obsessive-compulsive disorder is moderate to high At least two first-line drugs for the treatment of obsessive-compulsive disorder have not responded despite a sufficient dose and 12-week course of treatment.

Exclusion criteria

Exclusion criteria: Simultaneous onset of other psychiatric disorders based on diagnostic and statistical manual of mental disorders except major depressive disorder Seizures, pregnancy, unstable medical conditions Brain metal implants, pacemaker, inner ear prosthesis

Design outcomes

Primary

Measure	Time frame
Obsessive-compulsive score in the Yale-Brown questionnaire. Timepoint: Completion of the questionnaire of patients in both groups in three shifts, one day before the start of rTMS treatment, one day after the completion of the treatment period and after the quarterly follow-up. Method of measurement: Yale-Brown Questionnaire.	—

Secondary

Measure	Time frame
Anxiety score. Timepoint: Completion of the questionnaire of patients in both groups in three shifts, one day before the start of rTMS treatment, one day after the completion of the treatment period and after the quarterly follow-up. Method of measurement: Hamilton Anxiety Questionnaire (HAM-A).;Depression score. Timepoint: Completion of the questionnaire of patients in both groups in three shifts, one day before the start of rTMS treatment, one day after the completion of the treatment period and after the quarterly follow-up. Method of measurement: Hamilton Depression Questionnaire.	—

Measure

Time frame

Anxiety score. Timepoint: Completion of the questionnaire of patients in both groups in three shifts, one day before the start of rTMS treatment, one day after the completion of the treatment period and after the quarterly follow-up. Method of measurement: Hamilton Anxiety Questionnaire (HAM-A).;Depression score. Timepoint: Completion of the questionnaire of patients in both groups in three shifts, one day before the start of rTMS treatment, one day after the completion of the treatment period and after the quarterly follow-up. Method of measurement: Hamilton Depression Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMina Shaabani

Zanjan University of Medical Sciences

manaz@zums.ac.ir+98 24 3354 4001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026